Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database ; volume:16 ; number:1 ; day:11 ; month:7 ; year:2016 ; pages:1-7 ; date:12.2016
BMC cancer ; 16, Heft 1 (11.7.2016), 1-7, 12.2016
- Creator
-
Shin, Sangjin
- Contributor
-
Park, Chan Mi
Kwon, Hanbyeol
Lee, Kyung-Hun
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2482-z
- URN
-
urn:nbn:de:1111-2016071510813
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shin, Sangjin
- Park, Chan Mi
- Kwon, Hanbyeol
- Lee, Kyung-Hun
- SpringerLink (Online service)
Other Objects (12)
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
Gemcitabine in Recurrent Meningioma
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
Gemcitabine aktiviert H2AX über blockierte Replikationsgabel
Gemcitabine-Associated Pseudocellulitis: A Great Mimicker
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
Gemcitabine in Recurrent Meningioma
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
Gemcitabine aktiviert H2AX über blockierte Replikationsgabel
Gemcitabine-Associated Pseudocellulitis: A Great Mimicker
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer
Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
Gemcitabine in Recurrent Meningioma
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
Gemcitabine aktiviert H2AX über blockierte Replikationsgabel
Gemcitabine-Associated Pseudocellulitis: A Great Mimicker
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway
WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer